Market evolution: Halogenated corticosteroids (CN 293722) — 2015–2025

Introduction

Halogenated derivatives of corticosteroidal hormones (CN 293722) constitute a strategically important class of active pharmaceutical ingredients (APIs) used in anti-inflammatory, immunosuppressive, and respiratory therapies. Between 2015 and 2025, the EU's external trade in this product category underwent a profound structural transformation. The Union moved from a near-balanced trade position to a pronounced deficit in value terms, while simultaneously experiencing a dramatic collapse in export volumes. At the same time, import channels consolidated around a small number of partners — above all Singapore — and the EU's domestic production base appears to have expanded substantially, fundamentally altering the bloc's net import reliance. This report examines these dynamics across three axes: the volume–value divergence in EU exports, the reconfiguration of import supply chains, and the broader implications for the EU's strategic autonomy in corticosteroid APIs.

For an overview of EU trade in CN 293722, the data window spans 2015–2025 at annual frequency.

1. The Vanishing Volume: How EU Exports Shifted from Bulk to High-Value

The most striking feature of EU trade in CN 293722 over the decade is the near-total disappearance of export volume. Quantities shipped to non-EU partners fell by 94.4%, from 658 tonnes in 2015 to just 37 tonnes in 2025, even as unit values surged almost ninefold. This suggests a fundamental repositioning of the EU's role — from a bulk exporter of corticosteroid intermediates to a niche supplier of higher-value or more specialised products.

1.1 Export value halved while volumes collapsed

The decline in value (−49.9%) is far less severe than the decline in mass (−94.4%), indicating that the EU's remaining exports command dramatically higher prices per tonne. This pattern is consistent with a shift from bulk corticosteroid intermediates toward finished-dosage or highly purified specialty APIs.

1.2 The United Kingdom and United States absorbed most of the decline

The partner-level breakdown shows that EU exports to the two largest destinations fell dramatically:

The US and UK together lost over €176 M in EU-origin exports. Conversely, India (+197.9%) and Brazil (+38.2%) emerged as growth destinations, though from smaller bases. This geographic rebalancing may reflect both post-Brexit trade friction with the UK and a shift of corticosteroid formulation capacity toward emerging markets.

1.3 Ireland's export collapse was emblematic of a broader restructuring

Among EU Member State reporters, Ireland experienced the most dramatic reversal: exports fell from €71.0 M in 2015 to just €1.0 M in 2025 (−98.5%). Belgium dropped from €142.9 M to €46.8 M (−67.2%). Only Italy maintained a relatively stable position (€116.1 M → €103.4 M, −10.9%), suggesting its export base was less dependent on the bulk intermediate segment that eroded over the period. Spain even grew modestly (+29.3% to €13.7 M).

1.4 Two major export price shocks underscore the turbulence

The volatility analysis detected two significant price shocks in EU exports:

• United States (2018): An abnormal price shift of +290.7% with an abnormality score of 22.1, affecting flows that represented 64.5% of export value. This likely reflects a compositional change — as bulk volumes fell, the remaining shipments were higher-value products, mechanically inflating average prices.
• United Kingdom (2020): An extraordinary +1,123.2% price shift (abnormality 14.3), affecting 35.5% of export value. This coincides with the onset of COVID-19 and the UK's transition out of the EU single market, both of which disrupted established supply chains.

These shocks were not random supply disruptions but structural inflection points in the composition of EU trade flows.

2. The Singapore Corridor and the Consolidation of Import Supply Chains

While exports imploded in volume, EU import values proved more resilient, rising 14.6% from €396.6 M to €454.6 M over the period. However, this headline stability masks a dramatic concentration of imports around a single dominant partner: Singapore, which accounted for the vast majority of import value by 2025. The import concentration index confirms this trend, with the Herfindahl–Hirschman Index (HHI) by value rising from 5,479 to 6,441 (+17.5%).

2.1 Singapore became the overwhelmingly dominant import source

By 2025, Singapore alone represented roughly 80% of EU extra-bloc imports in value terms, up from approximately 73% in 2015. The full partner view shows that Singapore's import value peaked at €450.5 M during the period, reinforcing its centrality. This level of concentration raises strategic concerns: the EU's access to halogenated corticosteroid APIs depends critically on trade flows transiting through or originating in Singapore.

2.2 Import quantities fell even as values rose, driving unit prices sharply higher

Import unit prices rose by 50.5%, reaching nearly €10 M per tonne by 2025. This is consistent with the broader pharmaceutical trend of increasing API potency and value density, but it also suggests that the EU is importing increasingly refined or finished-stage products rather than raw intermediates.

2.3 Belgium consolidated its position as the EU's main import gateway

Among EU Member States receiving imports, Belgium's share grew substantially, rising from €257.2 M to €308.9 M (+20.1%). Belgium likely functions as the primary entry point for Singapore-origin corticosteroid APIs, given its port infrastructure and pharmaceutical logistics hubs. Spain also grew strongly (+165.4% to €42.4 M), while France and Italy saw modest declines. Ireland's imports surged from a negligible €160 K to €2.3 M, possibly reflecting post-Brexit re-routing of supply chains.

3. From Import Dependence to Production Powerhouse: The EU's Strategic Reorientation

The most transformative — and in some ways most surprising — development in EU corticosteroid trade over this decade is the apparent reversal of the bloc's net import reliance. In 2015, the EU depended on extra-bloc imports for 64.3% of its apparent consumption. By 2025, this figure had swung to −34.9%, indicating that the EU had become a net exporter relative to its domestic production base. This shift was driven not by a collapse in imports but by a massive expansion in reported EU production.

3.1 EU production appears to have expanded enormously

According to the production volume data, EU production (measured in gross tonnage, GT) grew from 618.7 million GT to 40.0 billion GT, while production value rose from €1.09 billion to €24.0 billion. These figures represent increases of 6,365% and 2,102% respectively — extraordinary magnitudes that warrant cautious interpretation. Such growth could reflect a genuine expansion of corticosteroid manufacturing capacity in the EU (potentially accelerated by pandemic-era API reshoring incentives), changes in reporting methodology, or the inclusion of previously unreported production streams. Regardless of the precise drivers, the trajectory fundamentally altered the EU's strategic calculus.

3.2 The EU trade balance swung from slight surplus to deep deficit in value

Despite becoming a net exporter in volume terms relative to production, the EU's trade balance in value deteriorated sharply:

The swing from +€236.5 M to −€254.8 M represents a deterioration of nearly €500 M. This apparent paradox — growing production but widening trade deficit — can be reconciled by the unit-price dynamics described above: the EU imports high-value finished APIs (average €9.9 M/tonne) while exporting lower-value intermediates or smaller volumes at varied price points.

3.3 Italy and Spain emerged as the EU's specialised production centres

The specialisation analysis for 2025 reveals clear geographic concentration of EU comparative advantage:

Italy alone accounts for one-third of EU production in this category, with an RCA of 4.16 indicating strong international competitiveness. The concentration of production in a handful of southern and western European states aligns with the broader geography of the European pharmaceutical API industry.

3.4 Export diversification improved as import dependency grew more concentrated

A notable asymmetry characterises the evolution of trade concentration. While import concentration by value rose (HHI from 5,479 to 6,441), export concentration fell markedly (HHI from 2,131 to 1,124, −47.2%). The EU's remaining exports are now spread across more diverse partners — including emerging markets like India, Brazil, Egypt, and Bangladesh — while its imports depend ever more heavily on Singapore. This divergence creates an asymmetric risk profile: diversified demand exposure but concentrated supply vulnerability.

Conclusion

The EU's trade in halogenated corticosteroid derivatives (CN 293722) underwent a fundamental transformation between 2015 and 2025. The most visible change was the collapse of export volumes by 94.4%, which repositioned the EU from a major bulk exporter to a niche, high-unit-value supplier. Simultaneously, imports consolidated around Singapore, which by 2025 accounted for roughly four-fifths of extra-bloc import value — a concentration level that presents clear supply-chain risk. Against this backdrop, EU domestic production appears to have expanded dramatically, flipping the bloc's net import reliance from +64% to −35% and altering the EU's strategic positioning. However, this expansion did not translate into trade surplus: the EU ran a €255 M deficit in 2025, reflecting the high cost of imported finished APIs. The key challenge for EU policymakers lies in reconciling the growth in domestic production capacity with the persistent trade deficit and the heavy reliance on Singapore-centred supply chains. Italy, Spain, and France — the bloc's most specialised producers — will be central to any strategy aimed at strengthening the EU's autonomy in this critical pharmaceutical segment.